Skip to main content
. 2022 Oct 14;9:926979. doi: 10.3389/fcvm.2022.926979

FIGURE 6.

FIGURE 6

Comparison of SGLT2 inhibitor vs. control group on the risks of (A) AKI; (B) DKA; (C) Volume Depletion. SGLT2, sodium-glucose cotransporter 2; AKI, acute kidney injury; DKA, diabetic ketoacidosis.